Form 4: AC Immune CEO Sells Shares Under 10b5-1 Plan

AC Immune SA's CEO, Andrea Pfeifer, reported the sale of 10,000 common shares for $2.7935 each under a pre-arranged trading plan.

Summary

• Andrea Pfeifer, CEO of AC Immune SA, reported a transaction on May 15, 2026.
• The transaction involved the sale of 10,000 common shares at a weighted average price of $2.7935.
• These shares were sold as part of a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this transaction, Ms. Pfeifer beneficially owns 3,820,288 common shares directly.
• An additional 14,000 shares are held indirectly by her spouse.
• The filing also notes that 1,921,005 common shares are held underlying outstanding restricted share units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While an insider sale can be a negative signal, the execution under a 10b5-1 plan indicates a pre-planned strategy rather than a reaction to current company performance.

Negatives

• The CEO sold a portion of her holdings, which could be perceived negatively by the market, although it was executed under a 10b5-1 plan.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which primarily reports a past transaction.

Industry Context

StockSavvy.ai notes that insider sales, even under a 10b5-1 plan, can sometimes lead to short-term market scrutiny. However, the existence of a 10b5-1 plan suggests a pre-determined strategy for managing personal holdings, mitigating concerns about opportunistic selling based on non-public information.

Stakeholder Impact

• Shareholders: May interpret the CEO's sale as a signal, though the 10b5-1 plan mitigates concerns about insider knowledge. The sale represents a small fraction of the CEO's total holdings.

Key Dates

Keywords

AC Immune SA, ACIU, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, CEO, Beneficial Ownership